VCM
RCKT icon

Versant Capital Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Versant Capital Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-266
Closed -$952 – 2836
2026
Q1 		$952 Buy
+266
New +$1.06K ﹤0.01% 2660
2025
Q1 		– Sell
-198
Closed -$2.49K – 2606
2024
Q4 		$2.49K Buy
+198
New +$2.98K ﹤0.01% 2004

Other funds holding RCKT

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Versant Capital Management's RCKT Position: Q2 2026 in Review

Versant Capital Management sold out of Rocket Pharmaceuticals (RCKT) in Q2 2026, closing a stake of 266 shares — an estimated $952 sold.

Versant Capital Management first reported a position in RCKT in Q4 2024 and held it in 2 quarters. The position peaked at $2.49K in Q4 2024. 19 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Versant Capital Management reported no remaining Rocket Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Versant Capital Management sold 266 Rocket Pharmaceuticals shares in Q2 2026, an estimated $952.
  • Versant Capital Management first reported a position in Rocket Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Versant Capital Management's Rocket Pharmaceuticals position peaked at $2.49K in Q4 2024.
  • 19 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.